Pepper(@wearpepper) 's Twitter Profile Photo

Meet the bra designed just for small boobs that fits like a second skin ☁️ No more cup gaps, awkward padding or digging wires. Just you in all your glory 🔥

account_circle
Kathrin Heinrich(@heinrich_kat) 's Twitter Profile Photo

On the train home from . Tired but super excited. What an incredible few days 🤩 one of the best meetings I attended so far I would say… ESMO - Eur. Oncology traintoandfromESMO

On the train home from #ESMO22. Tired but super excited. What an incredible few days 🤩 one of the best meetings I attended so far I would say… @myESMO @TraintoESMO
account_circle
TARGED(@WebTarged) 's Twitter Profile Photo

ESMO 2022'den BildiriYORUM ile ESMO 2022'de pratiği değiştirecek tüm çalışmaları birlikte tartışıyoruz!

ESMO 2022'den BildiriYORUM ile ESMO 2022'de pratiği değiştirecek tüm çalışmaları birlikte tartışıyoruz!
#ESMO2022 #ESMO22
account_circle
Luis Castelo-Branco (MD; PharmD; PhD)(@LuisCB_MedPharm) 's Twitter Profile Photo

Following the fantastic -2 data, presented during would we be able in the future to cure stageII/III CRC-MSI-H just with ICIs and without a morbid surgery for our patients? (Close FU with scans +ctDNA)?

Following the fantastic #NICHE-2 data, presented during #ESMO22 would we be able in the future to cure  stageII/III CRC-MSI-H just with ICIs and without a morbid surgery for our patients? (Close FU with scans +ctDNA)?
account_circle
Andrea Malfettone(@AMalfettonePhD) 's Twitter Profile Photo

study for pts with -mut platinum/IO pretreated
🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel!
✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002)
✅ORR: 28.1 vs 13.2%
⬇️grade≥3 TRAEs
Congrats Melissa L. Johnson & team!
OncoAlert

#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC
🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel!
✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002)
✅ORR: 28.1 vs 13.2%
⬇️grade≥3 TRAEs
Congrats @MLJohnsonMD2 & team!
#ESMO22 @OncoAlert
account_circle
Andreas.Koulouris(@DrKoulouris) 's Twitter Profile Photo

The double of 2021 Best ESMO Exam & 2022 fellowship is a great honour for me. Grateful to ESMO - Eur. Oncology!
Special thanks to Dr. Hess & Jordan for the outstanding 2021 ESMO Academy, as well as Evandro de Azambuja, MD, PhD & Teresa Amaral, MD, PhD for this memorable ceremony during the 🔥🇫🇷

The double #award of 2021 Best ESMO Exam & 2022 fellowship is a great honour for me. Grateful to @myESMO! 
Special thanks to Dr. Hess & Jordan for the outstanding 2021 ESMO Academy, as well as @E_de_Azambuja & @TeresaSAmaral for this memorable ceremony during the #esmo22🔥🇫🇷
account_circle
Turajlic Lab @ The Crick(@TurajlicLab) 's Twitter Profile Photo

ESMO - Eur. Oncology⁩ great programme- congrats to ⁦Charles Swanton⁩ and ⁦FabriceAndre⁩! (and commiserations to ⁦Toni Choueiri, MD⁩ and James Larkin for the losses on the football pitch- better get training…)

#ESMO22 ⁦@myESMO⁩ great programme- congrats to ⁦@CharlesSwanton⁩ and ⁦@FAndreMD⁩! (and commiserations to ⁦@DrChoueiri⁩ and James Larkin for the losses on the football pitch- better get training…)
account_circle
Maeve Hennessy(@HennessyMaeve) 's Twitter Profile Photo

Super to be back @ presenting collaborative work re imaging biomarkers of response in HER2 breast ca - ultimate goal of individualising tx. Inspired after a weekend of learning & catching up with ⭐️colleagues Cancer Research @UCC Johns Hopkins Kimmel Cancer Center @breakthrocancer Translational Breast Cancer Research Consortium HealthResearchBoard

Super to be back @#ESMO22 presenting collaborative work re imaging biomarkers of response in HER2 breast ca - ultimate goal of individualising tx. Inspired after a weekend of learning & catching up with ⭐️colleagues @CanResUCC @hopkinskimmel @breakthrocancer @TheTBCRC @hrbireland
account_circle
Gonzalo Recondo(@GRecondoMD) 's Twitter Profile Photo

Codebreak 200, randomized trial of Sotorasib vs Docetaxel in pts w/ KRAS G12C mutant NSCLC pre treated with chemo & IO :
➡️ PFS 5.6 vs 4.5 mo (HR 0.66)
➡️ ORR 28.1 % vs. 13.2%
➡️ DCR 82.5% vs 60.3%
➡️ Improved safety profile & PROs as expected with sotorasib

Codebreak 200, randomized trial of Sotorasib vs Docetaxel in pts w/ KRAS G12C mutant NSCLC pre treated with chemo & IO #ESMO22:
➡️ PFS 5.6 vs 4.5 mo (HR 0.66)
➡️ ORR 28.1 % vs. 13.2%
➡️ DCR 82.5% vs 60.3%
➡️ Improved safety profile & PROs as expected with sotorasib
account_circle
TECENTRIQ® (atezolizumab) HCP(@TecentriqHCP) 's Twitter Profile Photo

In 1L unresectable or mHCC, review the OS and PFS from the IMbrave150 trial. See the data now! Please see full Pl: bit.ly/TCQPI

account_circle
Pablo Cresta(@pablo_cresta) 's Twitter Profile Photo

has ended and it was a fantastic experience.
Many thanks to @MyESMO for awarding me with the ! Clearly, it is a landmark in my personal and professional development🚀. Thank you also to Evandro de Azambuja, MD, PhD and Teresa Amaral, MD, PhD for their support!🤗

1/4👇

#ESMO22 has ended and it was a fantastic experience.
Many thanks to @MyESMO for awarding me with the #esmoresearchfellowship! Clearly, it is a landmark in my personal and professional development🚀. Thank you also to @E_de_Azambuja and @TeresaSAmaral for their support!🤗

1/4👇
account_circle
Niamh Coleman, MD PhD(@niamhjcoleman) 's Twitter Profile Photo

Thrilled to have been at to present our work on non-v600 BRAF alterations. As always,v grateful for the expert mentorship of Vivek Subbiah, MD & collaborations MD Anderson Cancer Center Mohamed Alaa Gouda In the words of the great Razelle Kurzrock, MD - if it’s a target,it’s a pan-cancer target! 🎯🎯

Thrilled to have been at #ESMO22 to present our work on non-v600 BRAF alterations. As always,v grateful for the expert mentorship of @VivekSubbiah & collaborations @MDAndersonNews @mgoudaMD In the words of the great @Dr_R_Kurzrock - if it’s a target,it’s a pan-cancer target! 🎯🎯
account_circle
Myriam Chalabi(@MyriamChalabi) 's Twitter Profile Photo

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this.

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot
account_circle
Inês Pires da Silva(@inespiresilva) 's Twitter Profile Photo

It was a great pleasure to present the highlights for the investigational Immunotherapy track . See you next year in Madrid .

It was a great pleasure to present the highlights for the investigational Immunotherapy track #ESMO22. See you next year in Madrid #ESMO23.
account_circle